BIOMAT Database Logo BIOMAT Database Logo

Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. 1998

H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Division of Endocrinology, Department of Medicine III, University of Vienna, Währinger Gürtel 18-20 A-1090 Vienna, Austria.

Reduced bone mineral density (BMD) and the prevalence for osteoporotic vertebral fractures are symptoms of growth hormone deficiency (GHD) syndrome, and GH replacement therapy is now available for GH-deficient adults. We investigated the long-term effects of GH replacement therapy on bone mineral density (BMD) and bone metabolism in 19 adult patients with GHD over a period of 18 months. In response to GH treatment, the initially decreased IGF-I concentrations rose significantly during 18 months of therapy to levels within the normal range (matched for sex and age) (mean change 158.1 +/- 50.8 ng/ml, P < 0.001). Parameters of bone formation such as osteocalcin (OC) and procollagen I-C-Peptide (PICP) showed a significant increase in the first 6 months of therapy, followed by a slight decrease in the next months. Markers of bone resorption (CrosslapsR and deoxypyridinoline (D-Pyr) also increased significantly with a peak value after 6 months and all parameters except PICP remained above baseline values after 18 months. BMD of the femoral neck (FN) showed an increase after 18 months of therapy (mean change 0.01 +/- 0.03 g/cm2 after 18 months, n.s.). However, the increase in BMD was significant only in the lumbar spine (LS) (mean change 0.03 +/- 0.04 g/cm2, P < 0.05 after 18 months). We conclude that GH replacement therapy in adult patients with GHD over a period of 18 months causes a pronounced increase in bone turnover mainly during the first 12 months of therapy and increases BMD of the lumbar spine and the femoral neck after 18 months.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008159 Lumbar Vertebrae VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE. Vertebrae, Lumbar
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D001846 Bone Development The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS. Bone Growth
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen

Related Publications

H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Reduced bone mineral density in patients with adult onset growth hormone deficiency.
March 1994, The Journal of clinical endocrinology and metabolism,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy.
January 1995, European journal of endocrinology,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
January 1993, The Journal of pediatrics,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency.
January 2008, Pituitary,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
[Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
October 2004, Medizinische Klinik (Munich, Germany : 1983),
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.
March 2024, Haematologica,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Reduced Bone Mineral Density in Middle-Aged Male Patients with Adult Growth Hormone Deficiency.
July 2022, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Bone mineral density and biochemical parameters of bone turnover in children with growth hormone deficiency.
January 1996, Hormone research,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.
January 2023, International journal of endocrinology,
H Kotzmann, and M Riedl, and P Bernecker, and M Clodi, and F Kainberger, and A Kaider, and W Woloszczuk, and A Luger
Growth hormone deficiency during puberty reduces adult bone mineral density.
December 1992, Archives of disease in childhood,
Copied contents to your clipboard!